Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOvoca Bio Regulatory News (OVB)

  • There is currently no data for OVB

Holding(s) in Company

4 Nov 2021 15:53

RNS Number : 4116R
Ovoca Bio PLC
04 November 2021
 

Standard Form TR-1

Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the Central Bank of Ireland)i

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

OVOCA BIO PUBLIC LIMITED COMPANY

17 Pembroke Street Upper, Dublin 2 D02 AT22 Ireland

LEI: 213800ST2AK5XQ1O5207

ISIN: IE00B4XVDC01

2. Reason for the notification (please tick the appropriate box or boxes):

[x] An acquisition or disposal of voting rights

[ ] An acquisition or disposal of financial instruments

[ ] An event changing the breakdown of voting rights

[ ] Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv :

Name: Alexandr Mogutov

City and country of registered office (if applicable):

4. Full name of shareholder(s) (if different from 3.)v:

 

5. Date on which the threshold was crossed or reachedvi: 1 Nov 2021

 

6. Date on which issuer notified: 1 Nov 2021

 

7. Threshold(s) that is/are crossed or reached: 12%

 

8. Total positions of person(s) subject to the notification obligation:

 

% of voting rights attached to shares (total of 9.A)

% of voting rights through financial instruments(total of 9.B.1 + 9.B.2)

Total of both in % (9.A + 9.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

14.29%

 

14.29%

81,563,806

 

Position of previous notification (if applicable)

 

 

 

 

 

9. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii:

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

 

Direct

 

 

Indirect

 

 

Direct

 

 

Indirect

 

IE00B4XVDC01

11,656,203

 

14.29%

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL A

11,656,203

 

14.29%

 

 

B 1: Financial Instruments according to Regulation 17(1)(a) of the Regulations

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL B.1

 

 

 

B 2: Financial Instruments with similar economic effect according to Regulation 17(1)(b) of the Regulations

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash settlementxii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL B.2

 

 

          

 

10. Information in relation to the person subject to the notification obligation (please tick the applicable box):

 

[x ] Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.xiii

 

[ ] Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv:

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

11. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of [date]

 

 

 

12. Additional informationxvi:

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFLFEELILSIIL
Date   Source Headline
5th Feb 20267:00 amRNSChange of Name
28th Jan 20268:00 amRNSReadmission - Ovoca Bio PLC
28th Jan 20267:00 amRNSFirst Day of Dealings on AIM
27th Jan 20262:32 pmRNSResult of Meeting
31st Dec 20258:00 amRNSSchedule One - Ovoca Bio Plc
31st Dec 20258:00 amRNSSchedule One - Ovoca Bio Plc
31st Dec 20257:00 amRNSNotice of AGM
31st Dec 20257:00 amRNSPublication of Admission Document
31st Dec 20257:00 amRNSPublication of Admission Document
31st Dec 20257:00 amRNSNotice of AGM
13th Nov 20257:00 amRNSChange of Broker
30th Sep 20251:09 pmRNSReplacement Half Year Report
30th Sep 20257:00 amRNSHalf-year Report
26th Jun 20257:00 amRNSPublication of 2024 Annual Report
5th Jun 20257:00 amRNSDelisting from Euronext Growth Exchange
7th May 20257:30 amRNSSuspension - Ovoca Bio plc
7th May 20257:00 amRNSProposed Acquisition, Disposal & Reverse Takeover
3rd Mar 20252:00 pmRNSManagement Changes
18th Dec 20246:00 pmRNSResult of AGM
18th Nov 20247:00 amRNSNotice of AGM
11th Oct 20245:30 pmRNSHolding(s) in Company
9th Oct 20245:45 pmRNSSale of Treasury Shares
25th Sep 20247:00 amRNSHalf-year Report
2nd Sep 20242:30 pmRNSConsultancy Agreement
15th Jul 20247:00 amRNSDirector/PDMR Shareholding
15th Jul 20247:00 amRNSDirectorate Change
28th Jun 20247:00 amRNSAnnual Financial Report
23rd Jan 20247:00 amRNSHolding(s) in Company
1st Dec 202312:00 pmRNSResult of AGM
7th Nov 20239:15 amRNSNotice of AGM
28th Sep 20237:00 amRNSInterim Results
31st Aug 20237:00 amRNSSummary Results of Phase II Study for Orenetide
30th Jun 20237:00 amRNSAnnual Financial Report
12th Jun 20237:00 amRNSUpdate on Completion Timelines for Phase II Study
16th Mar 20234:35 pmRNSPrice Monitoring Extension
16th Mar 20232:05 pmRNSSecond Price Monitoring Extn
16th Mar 20232:00 pmRNSPrice Monitoring Extension
16th Mar 20239:05 amRNSSecond Price Monitoring Extn
16th Mar 20239:00 amRNSPrice Monitoring Extension
8th Mar 20237:00 amRNSDisposal of Russian Assets
14th Feb 20234:41 pmRNSSecond Price Monitoring Extn
14th Feb 20234:35 pmRNSPrice Monitoring Extension
14th Feb 20232:05 pmRNSSecond Price Monitoring Extn
14th Feb 20232:00 pmRNSPrice Monitoring Extension
13th Feb 20239:00 amRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
28th Oct 20227:00 amRNSResult of AGM
6th Oct 20222:30 pmRNSNotice of AGM
30th Sep 20227:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.